Table 2.

Risk estimates (ORs) and 95% CIs for TP53 polymorphisms in CIN3+/persistent HPV cases compared with random controls, adjusted for age

TP53 polymorphismGenotypeCIN3+/persistent HPV cases (n = 844)Population controls (n = 436)OR*95% CI*Ptrend
rs17887200AA7313851.00.52
22369bp 3′ of STP A>GAG101451.20.821.7
GG220.550.083.9
rs9894946CC7123661.00.82
22342bp 3′ of STP T>CCT119680.910.651.3
TT721.90.389.0
rs1614984CC4702441.00.99
21226bp 3′ of STP C>TCT3061521.10.821.3
TT65360.930.601.4
rs12951053TT5813231.00.05
IVS7+92 T>GGT2381011.31.01.7
GG1981.30.583.1
rs12947788CC5833241.00.09
IVS7+72 T>CCT2431041.31.01.7
TT1581.10.452.6
rs1625895GG6303321.00.18
IVS6+62 A>GAG194971.10.801.4
AA1724.41.019.0
rs2909430AA6583451.00.34
IVS4-91 A>GAG166861.00.761.4
GG1216.10.7947.5
rs9895829TT7493791.00.98
IVS4-125 T>CCT55310.890.571.4
CC512.50.2921.4
rs1042522 (Pro72Arg)bGG3882341.00.002
Ex4+119 C>GCG3351601.30.991.6
CC111371.81.22.7
rs1642785GG3832131.00.04
IVS2+38 C>GCG3571831.10.851.4
CC94311.71.12.6
rs8079544GG7884041.00.70
IVS1-112 G>AAG53290.930.581.5
AA320.770.134.6
  • * Adjusted for age.

  • Numbers do not add up to totals because of missing values.